about
Possible induction of mania by buspironeDepression or menopause? Presentation and management of major depressive disorder in perimenopausal and postmenopausal women.Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders.Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials.Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma.eMindLog: Self-Measurement of Anxiety and Depression Using Mobile Technology.The functional anatomy, neurochemistry, and pharmacology of anxiety.Desvenlafaxine and weight change in major depressive disorderRecent perspectives on the diagnosis and treatment of generalized anxiety disorder.Dissolving the burden of generalized anxiety disorder.Symptomatic and syndromal anxiety and depression.High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial.The state of knowledge of chronic depressionThe Genain Quadruplets 25 years later: a diagnostic and biochemical followup.New insights into the diagnosis and pharmacologic management of generalized anxiety disorder.New goals in the treatment of depression: moving toward recovery.Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label studyIncidence and Timing of Taper/Posttherapy-Emergent Adverse Events Following Discontinuation of Desvenlafaxine 50 mg/d in Patients With Major Depressive Disorder.A meta-analysis of factors impacting detection of antidepressant efficacy in clinical trials: the importance of academic sites.Report by the ACNP Task Force on response and remission in major depressive disorder.Correlation between patient and clinician assessments of depression severity in the PREVENT study.Recovery and subsequent recurrence in patients with recurrent major depressive disorder.Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder.A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depressionThe combination of triiodothyronine (T3) and sertraline is not superior to sertraline monotherapy in the treatment of major depressive disorder.Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals?Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine.The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases.Bright Light Therapy as Augmentation of Pharmacotherapy for Treatment of Depression: A Systematic Review and Meta-Analysis.The assessment of trichotillomania.Schizophrenia and its treatment.A novel chemically induced animal model of human anxiety.Issues in the assessment of treatment response in panic disorder with special reference to fluvoxamine.Tiagabine for social anxiety disorder.Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study.
P50
Q28332884-BC72E038-8561-4598-B961-7852325E30CDQ30435798-B06530C0-4F46-475B-9E4E-D2A1D452D903Q30457142-D928EFE6-1767-429E-AA5C-6C9691C367D9Q30484593-A8E21ACE-6751-46C3-A255-E67E971D74C5Q30717215-B6DF79C7-C0BF-41DC-B9DB-EB2CFF9921DDQ33375926-985286C2-CE88-43F6-9A95-44A02C4E7346Q33562783-E32BA747-4898-4B03-8648-8B1888504D36Q33716733-B0F5AAA1-B71C-4B35-A46D-192DB5D8F800Q33775176-43B1FB0C-A6DD-4B01-A4B3-EE41089DBC58Q33816961-5C76196E-26F5-4E2D-8F45-62F42A1F98F5Q33902252-B8CDBB20-5C77-44E4-B4C1-AC2E6512C1C0Q34379431-1E80BAC8-BE5C-4E8A-B3BD-B4CE0D134B48Q34385348-4FB0550E-EA19-48EE-A120-97BD7B96459EQ34415522-BDECA880-D8E5-45F6-B7FF-F393E7BA0FC5Q34564349-FFCA6B18-773A-4E94-8CEA-70FC428AB4EEQ34642747-7DB9CB63-FD0F-4E06-9CA1-990AA54C0748Q34707019-24A694BC-A7F3-42A3-B22B-8C650DE83760Q34979313-E741F5AF-4E89-41B4-A7BC-494902DF49FDQ35029935-4FF8EBD0-222B-49DA-9655-E2044ACDEA49Q35062660-ED02E19D-BFBB-49E4-BCF8-3EDC85BAF9D1Q35746660-BEA76177-F010-4D49-8378-90DC13F7CCE5Q36403827-65D5384D-A9EE-49F0-853F-A91B12133148Q36516394-B577D57A-8A20-44BF-9F73-E6459BA1A754Q36890822-43D7DCAE-57D4-4106-9672-6A252AA1DC67Q36914727-582CD151-59FC-4E50-BC05-89B744375F6EQ36914736-DA1F2A85-C4F5-4462-A28C-BBDA54B61FA0Q36938416-D850F7FF-9D5A-4C83-A0D3-B49F4B4D320DQ37141494-B77DFE34-75E6-45C5-8B01-87865AA4FA29Q37392195-4BD64FE9-AFC8-4FDE-B9BE-8DDAA9435C60Q37634095-72A68D60-E56C-4327-B28C-9C37BB5A018AQ37772742-CB68F476-7157-49C0-AD09-4B3E486CBD4EQ38395078-3D1F1751-8F9D-47DC-BFE6-98DA7D81E778Q39005424-7374EA4A-6614-4752-A145-7BE204A7B346Q39397238-93899566-3926-4C46-8AB7-FCC564B5A1A0Q39471134-97E0B1CF-7D77-4670-9183-336B7E3202DDQ40093654-F7C08AF0-E02C-4279-9C13-68C824EE3517Q41498639-C4B7C76C-4B6A-4D87-A622-52F60BE676FFQ42619190-D2C7D4C6-BF6A-4E59-BCB2-74DFE5A91718Q42625295-9956AC34-5275-4550-B6FE-5681690D62AAQ42637049-3134472C-0311-4071-9EED-F2CE7C230DE6
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Philip Ninan
@ast
Philip Ninan
@en
Philip Ninan
@es
Philip Ninan
@nl
Philip Ninan
@sl
type
label
Philip Ninan
@ast
Philip Ninan
@en
Philip Ninan
@es
Philip Ninan
@nl
Philip Ninan
@sl
altLabel
Philip T Ninan
@en
prefLabel
Philip Ninan
@ast
Philip Ninan
@en
Philip Ninan
@es
Philip Ninan
@nl
Philip Ninan
@sl
P1006
P214
P244
P1006
P106
P21
P214
P244
P31
P496
0000-0001-6633-1142
P734
P735
P7859
lccn-n88185868